Article

Genetic Mutation Responsible for Form of Macular Degeneration

Author(s):

Researchers are getting closer to understanding the pathogenesis of one type of age-related macular degeneration.

Researchers are getting closer to understanding the pathogenesis of one type of age-related macular degeneration (AMD). In a paper published ahead of print in the journal Human Molecular Genetics, Ewan P. Ramsay of the Wellcome Trust Center for Cell-Matrix Research and the University of Manchester, and colleagues, described their work in investigating the mechanisms that lead to X-linked retinoschisis (XLRS), which they characterized as being “a monogenic form of macular degeneration.”

The researchers said, “In this study we analyze the assembly of retinoschisin through solution of the structure of the retinoschisin monomer coupled with cryo-EM analysis”. Retinoschisin is “an octameric retinal-specific protein,” they said, and “is essential for retinal architecture with mutations causing X-linked retinoschisis”.

“Despite the central role retinoschisin plays in the maintenance of retinal architecture, the mechanism by which it maintains the integrity of photoreceptor-bipolar cell synapses remains elusive,” the researchers noted, further describing the need for the present study.

Their analyses showed “a highly elongated structure” that “generates a ‘wedge’ shape which would allow for efficient assembly of the retinoschisin subunits into a ring structure.” They added, “The observation of mutation sites within the inter-octamer interface lead to the hypothesis that the hexadecamer complex may be required for retinoschisin function in the retina.”

Additionally, the researchers wrote, “The formation of a retinoschisin dimer of octamers complex would allow for co-localization of synaptic machinery on opposing membranes whilst providing structural support to the synapse.” If that complex were destabilized or lost, the researchers added there would be “loss of structural integrity and pathology.”

The authors concluded by suggesting that future studies should focus on “structurally characterizing these interactions.” They ended by saying, “In summary, we show effects of two classes of secreted XLRS mutations on the structure and stability of retinoschisin to provide further insights into their pathology.”

Related Coverage:

Dexamethasone Implant Improves Visual Acuity and Decreases Macular Thickness in Diabetic Macular Edema

Resvega Improved Retinal Structure, Stabilized Visual Acuity in Neovascular AMD Case Study

Potential New Treatment Approach for Age-related Macular Degeneration

Related Videos
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
© 2024 MJH Life Sciences

All rights reserved.